Adjunctive controlled topical application of tetracycline HCl in the treatment of localized persistent or recurrent periodontitis. Effects on clinical parameters and elastase-alpha1-proteinase inhibitor in gingival crevicular fluid.
35 patients receiving regular supportive periodontal therapy (SPT) and showing signs of localized persistent or recurrent periodontitis were enrolled in the study. Within 1 week after SPT, each patient had a tetracycline HCl loaded ethylene vinyl acetate co-polymer fiber placed into the periodontal pocket of 1 randomly selected tooth with persistent or recurrent periodontitis (test); the fiber was removed after 9.5+/-2.0 days. A non-adjacent tooth with persistent or recurrent periodontitis in a separate quadrant, which received no further treatment, served as a control. A total of 28 patients completed the 6-month study. Compared to control teeth, in test teeth at 6 months significantly (p<0.01) lower scores were found for gingival index, pocket probing depths, and PMN elastase-alpha1-proteinase inhibitor concentrations in gingival crevicular fluid. With the exception of plaque index scores, test teeth demonstrated significant reductions from baseline to 6 months in all parameters (p<0.05). Conversely, all parameter measurements in control teeth, except bleeding on probing, showed no significant difference between baseline and 6-month values. The results suggest that the use of controlled topical application of tetracycline HCl may improve periodontal health and reduce the risk of disease progression in localized persistent or recurrent periodontitis. Moreover, the effects of this application appear to be sustained for at least 6 months.
Flemmig
T F
TF
Department of Operative Dentistry and Periodontics, Julius Maximilians University, Würzburg, Germany.
Weinacht
S
S
Rüdiger
S
S
Rumetsch
M
M
Jung
A
A
Klaiber
B
B
D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D015921:Dental Implants; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005883:Gingival Crevicular Fluid / Q000166:cytology / Q000201:enzymology*; D005884:Gingival Hemorrhage / Q000628:therapy; D006801:Humans; D019272:Leukocyte Elastase / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000201:enzymology*; D010196:Pancreatic Elastase; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000188:drug therapy; D010518:Periodontitis / Q000188:drug therapy*; D011145:Polyvinyls; D012008:Recurrence; D013752:Tetracycline / Q000008:administration & dosage / Q000627:therapeutic use*; D000515:alpha 1-Antitrypsin / Q000032:analysis*
D000900:Anti-Bacterial Agents; D015921:Dental Implants; D011145:Polyvinyls; D000515:alpha 1-Antitrypsin; C037741:alpha 1-antitrypsin-leukocyte elastase complex; C016438:ethylenevinylacetate copolymer; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase; D013752:Tetracycline